SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Philippe Menu sold 4,400 shares of the stock in a transaction on Monday, April 13th. The stock was sold at an average price of $4.76, for a total value of $20,944.00. Following the completion of the sale, the insider directly owned 268,596 shares in the company, valued at $1,278,516.96. This represents a 1.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Philippe Menu also recently made the following trade(s):
- On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.68, for a total value of $17,433.00.
- On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total value of $9,152.94.
- On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total value of $13,552.00.
- On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total value of $11,688.00.
- On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $13,095.00.
- On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $2,912.32.
SOPHiA GENETICS Stock Performance
NASDAQ SOPH traded up $0.11 during trading hours on Tuesday, hitting $4.96. The company had a trading volume of 148,768 shares, compared to its average volume of 183,135. SOPHiA GENETICS SA has a fifty-two week low of $2.58 and a fifty-two week high of $5.70. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The business has a fifty day simple moving average of $4.74 and a 200-day simple moving average of $4.71. The firm has a market cap of $339.71 million, a P/E ratio of -9.73 and a beta of 1.04.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of SOPH. Savvy Advisors Inc. bought a new position in shares of SOPHiA GENETICS in the third quarter worth $48,000. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the third quarter worth $49,000. Perkins Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the fourth quarter worth $49,000. Quadrature Capital Ltd bought a new position in SOPHiA GENETICS during the fourth quarter valued at about $54,000. Finally, XTX Topco Ltd bought a new position in SOPHiA GENETICS during the fourth quarter valued at about $55,000. Institutional investors own 31.59% of the company’s stock.
Wall Street Analyst Weigh In
SOPH has been the subject of several recent analyst reports. BTIG Research reissued a “buy” rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Guggenheim increased their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $7.00.
About SOPHiA GENETICS
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Read More
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
